1:17-cv-00374 | Bristol-Myers Squibb Company et al v. Aurobindo Pharma USA Inc. | RPX Insight

Bristol-Myers Squibb Company et al v. Aurobindo Pharma USA Inc. DC CAFC
- 1:17-cv-00374
- D. Del.
- Judge: Leonard P. Stark
- Filed: 04/05/2017
- Closed: 08/13/2020
- Latest Docket Entry: 10/13/2021
- PACER

2

Plaintiffs

35

Defendants

2

Accused Products

2

Patents-in-Suit

1,227

Days in Litigation

Docket (889 Entries)

Campaign (31 Defendants)

Bristol-Myers Squibb Company et al v. Aurobindo Pharma USA Inc. DC CAFC
- 1:17-cv-00374
- D. Del.
- Judge: Leonard P. Stark
- Filed: 04/05/2017
- Closed: 08/13/2020
- Latest Docket Entry: 10/13/2021
- PACER

Docket (889 Entries)

Campaign (31 Defendants)

Litigation Complaint | RPX Insight

View Complaint

Appeals

20-2229
20-2252
20-2258

Cause of Action

Infringement

Market Sector

Biotech and Pharma

Court

District of Delaware

Assigned Judge

Leonard P. Stark

Outcome Summary

View Outcome Details

Validity and Enforceability Details

Infringement Details

Patent Information

Patents-in-Suit

Validity & Enforceability

US 6,967,208 B2

1 Detail

Claim #	Claim Text	Outcome
13	A compound according to claim 8, wherein the compound is: 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl-4,5,6,7-tetrahydro-1H-pyrazole-[3,4-c]pyridine-3-carboxamide or a pharmaceutically acceptable salt form thereof.	Valid Entry 735 Entry 739

US 9,326,945 B2

2 Details

Claim #	Claim Text	Outcome
21	The composition as defined in claim 12, wherein the pharmaceutical composition comprises 2.5 mg of apixaban.	Valid Entry 735 Entry 739
22	The composition as defined in claim 12, wherein the pharmaceutical composition comprises 5 mg of apixaban.	Valid Entry 735 Entry 739

Infringement

HEC Pharm USA Incorporated

1 Detail

Accused Product	Patent #	Claim #	Outcome
2.55 mg tablets of apixaban5 mg tablets of apixabanGeneric apixaban tablets, 2.5 mgGeneric apixaban tablets, 5 mg	US 9,326,945 B2	21, 22	Infringement Entry 735 Entry 739

Sigmapharm Laboratories LLC

2 Details

Accused Product	Patent #	Claim #	Outcome
2.55 mg tablets of apixaban5 mg tablets of apixabanGeneric apixaban tablets, 2.5 mgGeneric apixaban tablets, 5 mg	US 6,967,208 B2	13	Infringement Entry 735 Entry 739
2.55 mg tablets of apixaban5 mg tablets of apixabanGeneric apixaban tablets, 2.5 mgGeneric apixaban tablets, 5 mg	US 9,326,945 B2	21, 22	Infringement Entry 735 Entry 739

Sunshine Lake LLC

1 Detail

Accused Product	Patent #	Claim #	Outcome
2.55 mg tablets of apixaban5 mg tablets of apixaban	US 9,326,945 B2	21, 22	Infringement Entry 735

Sunshine Lake Pharma Co Ltd

1 Detail

Accused Product	Patent #	Claim #	Outcome
Generic apixaban tablets, 2.5 mgGeneric apixaban tablets, 5 mg	US 9,326,945 B2	21, 22	Infringement Entry 739

Unichem Laboratories Limited

2 Details

Accused Product	Patent #	Claim #	Outcome
Generic apixaban tablets, 2.5 mgGeneric apixaban tablets, 5 mg	US 6,967,208 B2	13	Infringement Entry 739
2.55 mg tablets of apixaban5 mg tablets of apixabanGeneric apixaban tablets, 2.5 mgGeneric apixaban tablets, 5 mg	US 9,326,945 B2	21, 22	Infringement Entry 735 Entry 739